Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

CODX


Top 10 Correlated ETFs

CODX


Top 10 Correlated Stocks

CODX


In the News

06:00 30 Sep 2022 CODX

7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic's Over'

As people acclimatize to the new normal, it's time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.

06:03 30 Sep 2022 CODX

Why Co-Diagnostics Stock Slipped Today

Investors continued to avoid the company after its big second-quarter whiffs.

07:26 30 Sep 2022 CODX

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q2 2022 Results - Earnings Call Transcript

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman, President and Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Robert Burns - H.C. Wainwright & Co., LLC James Sidoti - Sidoti & Company, LLC Theodore O'Neill - Litchfield Hills Research, LLC Operator Good afternoon, and welcome to the Co-Diagnostics' Second Quarter 2022 Earnings Conference Call.

06:49 30 Sep 2022 CODX

CoDiagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of -166.67% and 75.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

05:01 30 Sep 2022 CODX

Co-Diagnostics ends 2Q with $96M in cash, expands infectious disease testing menu to include monkeypox

Co-Diagnostics Inc (NASDAQ:CODX) ended its second quarter of 2022 with a cash balance of US$96 million to help it progress development of its Co-Dx PCR Home testing platform for infectious diseases. During the three-month period to end June 30, 2022, the company completed the principal design for a monkeypox virus test and shipped testing reagents to its international distributor.

05:09 30 Sep 2022 CODX

Why Shares of Co-Diagnostics Stock Fell 10% on Tuesday

The stock dropped two days before reporting second-quarter earnings.

10:53 30 Sep 2022 CODX

CoDiagnostics, Inc. (CODX) Surges 5.8%: Is This an Indication of Further Gains?

CoDiagnostics, Inc. (CODX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

10:41 30 Sep 2022 CODX

Co-Diagnostics set to expand OEM deal with Bio Molecular Systems at AACC expo

Co-Diagnostics Inc (NASDAQ:CODX) (Co-Dx) has announced that it will be disclosing the global expansion of its original equipment manufacturer (OEM) agreement with Bio Molecular Systems (BMS) at the company's customer and distributor update today at the American Association for Clinical Chemistry's (AACC) Annual Scientific Meeting & Clinical Lab Expo. The molecular diagnostics firm said the expanded branding and distribution OEM agreement increases Co-Diagnostics' approved sales territories to 193 countries worldwide.

09:30 30 Sep 2022 CODX

Co-Diagnostics, Inc. to Announce Expansion of OEM Agreement with Bio Molecular Systems at AACC

SALT LAKE CITY , July 26, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be disclosing the global expansion of its OEM agreement with Bio Molecular Systems (BMS) at the Company's customer and distributor update today at AACC. Located in the Gold Coast area of Queensland, Australia, BMS includes the founders and senior personnel from the company responsible for inventing and developing the original Rotor-Gene Real-Time PCR instrument, with a reputation for expertise in developing innovative, versatile, robust, and easy-to-use products.

02:18 30 Sep 2022 CODX

CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests

CODX stock is up during early afternoon trading as Co-Diagnostics ships out monkeypox testing reagents to help deal with the outbreak. The post CODX Stock Pops as Co-Diagnostics Ships Out Monkeypox Tests appeared first on InvestorPlace.

Financial details

Company Rating
Buy
Market Cap
102.02M
Income
28M
Revenue
78.22M
Book val./share
4.45
Cash/share
2.96
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
09 Nov 2022
P/E
3.38
Forward P/E
-
PEG
-0.81
P/S
1.32
P/B
0.71
P/C
1.07
P/FCF
4.19
Quick Ratio
16.12
Current Ratio
17.06
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
0.93
EPS next Y
-
EPS next Q
-
EPS this Y
-20.13%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
562.64%
Revenue Q/Q
-77.87%
EPS Q/Q
-122.86%
-
-
-
-
SMA20
-14.2%
SMA50
-49.07%
SMA100
-31.67%
Inst Own
21.02%
Inst Trans
-2.13%
ROA
17%
ROE
21%
ROC
0.19%
Gross Margin
87%
Oper. Margin
38%
Profit Margin
36%
Payout
-
Shs Outstand
33.78M
Shs Float
33.63M
-
-
-
-
Target Price
9
52W Range
2.76-10.9
52W High
-68.2%
52W Low
+59%
RSI
41.2
Rel Volume
0.44
Avg Volume
669.22K
Volume
292.83K
Perf Week
3.58%
Perf Month
-17.62%
Perf Quarter
-46.01%
Perf Half Y
-51.3%
-
-
-
-
Beta
-0.769077
-
-
Volatility
0.11%, 0.25%
Prev Close
1.6%
Price
3.18
Change
11.58%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
000.012.793.39
Net income per share
-0.63-0.5-0.371.591.27
Operating cash flow per share
-0.29-0.33-0.331.051.42
Free cash flow per share
-0.3-0.33-0.341.031.4
Cash per share
0.320.080.051.773.11
Book value per share
0.35-0.080.12.54.66
Tangible book value per share
0.35-0.080.12.53.21
Share holders equity per share
0.35-0.080.12.54.66
Interest debt per share
0.030.160.0100
Market cap
32.11M27.97M45.24M343.09M198.37M
Enterprise value
28.58M28.92M44.35M300.11M109.76M
P/E ratio
-4.61-4.46-7.38.085.41
Price to sales ratio
4.19K700.7210.464.62.03
POCF ratio
-10-6.85-8.1912.184.83
PFCF ratio
-9.61-6.79-8.0212.534.91
P/B Ratio
8.34-26.4126.045.141.48
PTB ratio
8.34-26.4126.045.141.48
EV to sales
3.73K724.71206.314.031.12
Enterprise value over EBITDA
-4.33-4.75-7.367.012.39
EV to operating cash flow
-8.9-7.09-8.0310.662.67
EV to free cash flow
-8.55-7.02-7.8710.962.72
Earnings yield
-0.22-0.22-0.140.120.18
Free cash flow yield
-0.1-0.15-0.120.080.2
Debt to equity
00000
Debt to assets
0.171.680.220.060.16
Net debt to EBITDA
0.54-0.160.15-1-1.93
Current ratio
7.090.454.8315.169.14
Interest coverage
-14.71-45.33-55.37428.881.01K
Income quality
0.460.650.890.661.12
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
404.0489.4716.270.110.12
Research and developement to revenue
130.9334.16.380.040.15
Intangibles to total assets
00000.26
Capex to operating cash flow
0.040.010.02-0.03-0.02
Capex to revenue
-16.88-1.04-0.53-0.01-0.01
Capex to depreciation
-2.83-0.81-1.72-5.59-2
Stock based compensation to revenue
265.4633.385.060.040.06
Graham number
2.240.980.939.4511.53
ROIC
-1.137.66-3.120.620.31
Return on tangible assets
-1.49-4.04-2.80.60.31
Graham Net
0.25-0.130.042.092.8
Working capital
3.82M-1.3M1.26M63.85M102.52M
Tangible asset value
000092.57M
Net current asset value
3.64M-1.56M1.11M63.82M89.56M
Invested capital
0-1.8000
Average receivables
06.08M6.13M12.14M16.53M
Average payables
319.57K373.64K302.14K598.32K602.91K
Average inventory
4M4.01M4.1M8M5M
Days sales outstanding
0122.73223.0759.4277.99
Days payables outstanding
49.33K5.79K19.3513.1619.16
Days of inventory on hand
10.96K705.55640.09175.8963.2
Receivables turnover
02.971.646.144.68
Payables turnover
0.010.0618.8727.7319.05
Inventory turnover
0.030.520.572.085.78
ROE
-1.815.92-3.570.640.27
Capex per share
-0.010-0.01-0.03-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-06-30 for Q2

Metric History 2021-06-302021-09-302021-12-312022-03-31 2022-06-30
Revenue per share
0.951.040.70.670.15
Net income per share
0.340.40.260.35-0.08
Operating cash flow per share
0.430.40.170.230.05
Free cash flow per share
0.420.390.160.220.04
Cash per share
2.512.93.12.872.96
Book value per share
3.033.464.654.354.45
Tangible book value per share
3.033.463.23.123.14
Share holders equity per share
3.033.464.654.354.45
Interest debt per share
0000.020.02
Market cap
237.55M281.6M258.45M209.72M182.17M
Enterprise value
167.28M198.94M169.84M112.86M96.61M
P/E ratio
6.076.138.624.48-16.95
Price to sales ratio
8.689.3612.679.2436.27
POCF ratio
19.1224.4752.9826.87110.11
PFCF ratio
19.524.8354.3328.31158.85
P/B Ratio
2.722.811.921.421.26
PTB ratio
2.722.811.921.421.26
EV to sales
6.116.618.324.9719.23
Enterprise value over EBITDA
13.9314.5416.48.45-32.84
EV to operating cash flow
13.4617.2934.8114.4658.4
EV to free cash flow
13.7317.5435.7115.2384.24
Earnings yield
0.040.040.030.06-0.01
Free cash flow yield
0.050.040.020.040.01
Debt to equity
00000
Debt to assets
0.060.050.160.140.1
Net debt to EBITDA
-5.85-6.04-8.56-7.2529.08
Current ratio
19.124.839.149.6317.06
Interest coverage
1.12K1.2K1.14K862.3-67.24
Income quality
1.2710.650.67-0.62
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.090.10.160.130.49
Research and developement to revenue
0.170.20.110.170.77
Intangibles to total assets
000.260.240.26
Capex to operating cash flow
-0.02-0.01-0.02-0.05-0.31
Capex to revenue
-0.01-0.01-0.01-0.02-0.1
Capex to depreciation
-3.38-1.76-1.19-1.6-1.2
Stock based compensation to revenue
0.030.050.080.060.31
Graham number
4.815.565.25.812.88
ROIC
0.130.130.070.06-0.03
Return on tangible assets
0.110.110.060.09-0.02
Graham Net
2.733.152.82.732.81
Working capital
85.59M98.17M102.52M112.32M107.85M
Tangible asset value
0092.57M105.82M102.1M
Net current asset value
84.8M97.09M89.56M101.9M98.2M
Invested capital
00000
Average receivables
17.25M18.16M21.33M21.74M17.02M
Average payables
821.1K1.01M911.28K1.22M1.03M
Average inventory
4.51M4.1M3.45M4.9M4.8M
Days sales outstanding
41.9643.6292.2686.19220.29
Days payables outstanding
15.3521.7421.9933.3283.41
Days of inventory on hand
148.0989.7772.53134.4462.66
Receivables turnover
2.142.060.981.040.41
Payables turnover
5.864.144.092.71.08
Inventory turnover
0.6111.240.670.19
ROE
0.110.110.060.08-0.02
Capex per share
-0.01-0.010-0.01-0.02

Frequently Asked Questions

What is Co-Diagnostics, Inc. stock symbol ?

Co-Diagnostics, Inc. is a US stock , located in Salt lake city of Utah and trading under the symbol CODX

Is Co-Diagnostics, Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $10.5. The lowest prediction is $9 and the highest is $12

What is CODX stock prediction ?

With a median analyst target price of $9, 1 stock analysts have made 1 forecasts in last 90 days. $9 is the lowest and $9 is the greatest projection.

What is Co-Diagnostics, Inc. stock quote today ?

Co-Diagnostics, Inc. stock price is $3.18 today.

Is Co-Diagnostics, Inc. stock public?

Yes, Co-Diagnostics, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap